Amazon Biotech Announces a New Double-Blind Drug Trial Using AMZ 0026
Posted on: Tuesday, 25 October 2005, 21:00 CDT
Amazon Biotech, Inc. (OTC BB: AMZB) today announced that it has come to an agreement with a New York City AIDS clinic to do a forty patient double-blind study using AMZ 0026 together with and in comparison with a standard cocktail currently given to patients with AIDS. Full details of the study to follow shortly.
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ 0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ 0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market. Additional information on Amazon Biotech may be found at http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes,'' "expects,'' "anticipates,'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
CONTACT: LC Group Rick Lutz (404) 261-1196
SOURCE: Amazon Biotech, Inc
Source: MARKET WIRE
Related Articles
- Back on Job, Snow Looks Forward to Busy Schedule
- Heinz Announces Preliminary Proxy Voting Results; Looks Forward With Confidence to Executing Its Plans to Increase Shareholder Value
- Ebert Looks Forward to Return to Work
- Jones looks forward to New York test
- Taiwan "Looks Forward to Better Ties With Japan" After Election
- We Should All Look Forward to a Productive New School Year
- New champion Taylor looking forward to rematch
- Aniston Looks Forward Past 'Friends'
- UK Astronomers Look Forward to Looking Back
- Biotech Firms Look to Crack EU Markets
 |
 |
User Comments (0)
RSS Feeds